ALTAMIRA THERAPEUTICS LTD (CYTO) Forecast, Price Target & Analyst Ratings
NASDAQ:CYTO • BMG0360L1349
0.3 USD
-0.11 (-25.94%)
At close: Dec 19, 2024
0.262 USD
-0.04 (-12.67%)
After Hours: 12/19/2024, 10:21:17 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ALTAMIRA THERAPEUTICS LTD (CYTO).
Forecast Snapshot
Consensus Price Target
$5.41
+ 1,702.00% Upside
Next Earnings Forecast
Release DateN/A
ChartMill Buy Consensus
82.86%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$5.41
Upside
+ 1,702.00%
From current price of $0.30 to mean target of $5.41, Based on 7 analyst forecasts
Low
$5.35
Median
$5.41
High
$5.57
Price Target Revisions
1 Month
0.00%
3 Months
-35.44%
Price Target Summary
7 Wall Street analysts provided a forecast for the next 12 months for CYTO. The average price target is 5.41 USD. This implies a price increase of 1702% is expected in the next year compared to the current price of 0.3.
The average price target has been revised downward by 35.44% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.86%
CYTO was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about CYTO.
In the previous month the buy percentage consensus was at a similar level.
CYTO was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
Next Earnings Forecast Details
Next Earnings Details
Release DateN/A
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 60K | 310K 416.67% | 188.233K -39.28% | -100.00% | 5.835M | ||
| EBITDA YoY % growth | -13.18M -150.57% | -12.68M 3.79% | -1.876M 85.20% | N/A | N/A | N/A | |
| EBIT YoY % growth | -13.26M -151.14% | -12.8M 3.47% | -1.995M 84.41% | -9.106M -356.34% | -11.778M -29.35% | -8.297M 29.56% | |
| Operating Margin | -22,100.00% | -4,129.03% | -1,060.03% | N/A | N/A | -142.19% | |
| EPS YoY % growth | N/A | N/A | N/A | -2.70 | -1.19 55.85% | -1.64 -37.61% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-4.65%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
214.13%
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
ALTAMIRA THERAPEUTICS LTD / CYTO Forecast FAQ
Can you provide the average price target for ALTAMIRA THERAPEUTICS LTD stock?
7 analysts have analysed CYTO and the average price target is 5.41 USD. This implies a price increase of 1702% is expected in the next year compared to the current price of 0.3.
What is the consensus rating for CYTO stock?
The consensus rating for ALTAMIRA THERAPEUTICS LTD (CYTO) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.